Gabapentinoids for Chronic Low Back Pain: Limited Evidence, More Harm Than Benefit
Am Fam Physician. 2017 Dec 15;96(12):online.
Are gabapentinoids safe and effective in treating patients with chronic low back pain?
The existing data on gabapentinoids for chronic low back pain are limited in number and quality. The amount of pain reduction is low to moderate, and the rate of adverse effects is high. The few studies that assessed function found no improvement. (Level of Evidence = 2a –)
These authors searched two databases and the Cochrane clinical trials register to identify randomized trials of gabapentinoids (gabapentin [Neurontin], pregabalin [Lyrica]) for treating adults with back pain lasting at least three months. Two authors independently assessed the inclusion of articles, and they resolved disagreements by consensus or through third-party adjudication. Ultimately, they included eight small studies with three different comparison treatments. Most of the studies had methodological quality issues, including selection bias and inadequate concealment of randomization. Three studies with 185 patients compared gabapentin with placebo, finding minimal improvement in pain. Three studies with 332 patients compared pregabalin with other analgesics, finding pregabalin was more effective in average pain response. The remaining studies, which assessed pregabalin as an adjunct to pain management, were heterogeneous, and the authors chose not to pool the data. The largest of these studies, however, found that adding pregabalin did not improve pain.
We have commented often on the inconsistent reporting of treatment harms in clinical trials, and these studies are no exception. However, the authors were able to pool data and estimate the number needed to treat to harm (NNTH) for several adverse effects: dizziness (NNTH = 7; 95% confidence interval [CI], 4 to 30), fatigue (NNTH = 8; 95% CI, 4 to 44), altered mentation (NNTH = 6; 95% CI, 4 to 15), and vision disturbance (NNTH = 6; 95% CI, 4 to 13). The studies generally did not report on functional outcomes.
Study design: M
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.
A collection of POEMs published in AFP is available at http://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions